Endo International (NASDAQ:ENDP) Shares Up 12.8%

Share on StockTwits

Shares of Endo International PLC (NASDAQ:ENDP) (TSE:ENL) shot up 12.8% on Monday . The company traded as high as $2.57 and last traded at $2.55, 4,945,903 shares changed hands during trading. An increase of 19% from the average session volume of 4,138,867 shares. The stock had previously closed at $2.26.

A number of research firms recently weighed in on ENDP. JPMorgan Chase & Co. cut Endo International from a “neutral” rating to an “underweight” rating and set a $9.00 price target for the company. in a report on Monday, May 13th. Royal Bank of Canada reaffirmed a “hold” rating and set a $6.00 price target on shares of Endo International in a report on Thursday, August 8th. ValuEngine cut Endo International from a “sell” rating to a “strong sell” rating in a report on Tuesday, May 28th. Zacks Investment Research cut Endo International from a “buy” rating to a “hold” rating in a report on Wednesday, May 15th. Finally, Morgan Stanley set a $2.00 price target on Endo International and gave the company a “sell” rating in a report on Friday, August 9th. Four investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $8.48.

The company has a 50 day moving average price of $3.22 and a 200 day moving average price of $6.43. The company has a market capitalization of $511.65 million, a price-to-earnings ratio of 1.03 and a beta of 1.14.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its earnings results on Monday, August 5th. The company reported $0.52 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.47 by $0.05. The company had revenue of $699.71 million during the quarter, compared to analysts’ expectations of $694.60 million. Endo International had a negative return on equity of 129.30% and a negative net margin of 19.98%. The business’s revenue for the quarter was down 2.1% on a year-over-year basis. During the same period last year, the firm earned $0.76 EPS. Analysts forecast that Endo International PLC will post 2.17 EPS for the current year.

In other news, Director Roger H. Kimmel sold 34,951 shares of the firm’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $3.93, for a total value of $137,357.43. Following the transaction, the director now directly owns 148,309 shares in the company, valued at approximately $582,854.37. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.50% of the stock is owned by company insiders.

Large investors have recently bought and sold shares of the company. Signition LP bought a new position in shares of Endo International in the 1st quarter worth $139,000. First Quadrant L P CA boosted its position in shares of Endo International by 94.7% in the 1st quarter. First Quadrant L P CA now owns 24,513 shares of the company’s stock worth $197,000 after purchasing an additional 11,926 shares during the last quarter. Norges Bank bought a new position in shares of Endo International in the 4th quarter worth $21,218,000. Factorial Partners LLC bought a new position in shares of Endo International in the 1st quarter worth $193,000. Finally, Nordea Investment Management AB boosted its position in shares of Endo International by 37.5% in the 1st quarter. Nordea Investment Management AB now owns 177,700 shares of the company’s stock worth $1,427,000 after purchasing an additional 48,500 shares during the last quarter. Institutional investors and hedge funds own 91.68% of the company’s stock.

Endo International Company Profile (NASDAQ:ENDP)

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Further Reading: Equity Income

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.